SAN DIEGO, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the second quarter ended June 30, 2025, and provided pipeline and business updates.
Related Questions
How does the current valuation (P/E, EV/EBITDA, price-to-cash) compare to peers in the metabolic disease biotech space?
How did Aardvark Therapeutics' Q2 revenue and net loss compare to Wall Street expectations?
What guidance did the company provide for Q3 and full-year 2025 earnings and cash burn?
Are there any upcoming data readouts, FDA filings, or clinical trial milestones that could act as catalysts for the stock?
Did the company announce any new partnership, licensing deal, or financing that could impact dilution or cash runway?
What is the status of Aardvark's lead product candidates and how might their trial outcomes affect the stock price?
Did the earnings release provide any insight into the company's R&D spend efficiency or shift in strategic focus?
How might the reported cash position and burn rate affect the need for future equity raises or debt financing?
Is there any indication of changes in the competitive landscape that could affect Aardvark's market opportunity?
What technical indicators or trading volume patterns are emerging in response to this news release?